NCT04506086

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.